Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Side Effects Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nurse Suicide: Physiologic Sleep Health Promotion Trial

NCT06079853
View directory record Official record
Conditions
Suicide, Nurse's Role, Work Environment Adverse Effects, Sleep, Stress, Mental Health Wellness 1
Interventions
PureSomni Sleep Health Product Kit
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cortlandt Manor, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 25, 2026, 10:30 PM EDT
Terminated Phase 3 Interventional Results available

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

NCT00305643
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pain
Interventions
Capecitabine, Celecoxib, Radiation Therapy, Placebo
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCT00815854
View directory record Official record
Conditions
Schizophrenia
Interventions
Folic Acid, Placebo
Dietary Supplement · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 25, 2026, 10:30 PM EDT
Enrolling by invitation Not applicable Interventional

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

NCT07499128
View directory record Official record
Conditions
Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma, Lymphoma Mantle-cell, Immunotherapy, Cell and Tissue-Based Therapy, Cytokines, Monitoring Physiologic, Immune Monitoring, Wearable Electronic Devices, Thermometry, Body Temperature, Antibodies Bispecific, Receptors Chimeric Antigen
Interventions
TempTraq, VitalTraq
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy

NCT02796365
View directory record Official record
Conditions
Doxorubicin Induced Cardiomyopathy, Breast Cancer, Gastric Cancer, Leukemia
Interventions
Exercise
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 25, 2026, 10:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of an Informed Consent Statement Which Communicates the Risk of Adverse Events Associated With Dry Needling

NCT05560100
View directory record Official record
Conditions
Dry Needling
Interventions
Nominal Group Technique - 2 to 3 hour virtual meeting
Other
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 25, 2026, 10:30 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784
View directory record Official record
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Terminated Phase 1 Interventional

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

NCT00003926
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC)
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 25, 2026, 10:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

NCT02037347
View directory record Official record
Conditions
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions
Palifermin
Drug
Lead sponsor
Brett King
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Bridgeport, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 25, 2026, 10:30 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT07744126
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Duarte, California • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Completed No phase listed Observational Results available

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

NCT01099397
View directory record Official record
Conditions
Prediabetic State
Interventions
Oral glucose tolerance test
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 25, 2026, 10:30 PM EDT
Recruiting Not applicable Interventional

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer

NCT05874297
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Best Practice, Internet-Based Intervention, Questionnaire Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

NCT05476679
View directory record Official record
Conditions
Submental Fat
Interventions
RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 4 Interventional

A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort

NCT00268827
View directory record Official record
Conditions
HIV-1, AIDS
Interventions
Kaletra soft-gel capsules switched to Kaletra tablets, MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire
Drug · Device
Lead sponsor
AIDS Arms Inc.
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2007 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Translating ECHOS2 Into an mHealth Platform

NCT05923242
View directory record Official record
Conditions
Childhood Cancer, Cardiac Toxicity, Pediatric Cancer
Interventions
Computerized Intervention Authoring Software (CIAS)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

NCT00269620
View directory record Official record
Conditions
Contraception
Interventions
ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

NCT02133924
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
natalizumab, steroids
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT

NCT04158804
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
procalcitonin
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Torrington, Connecticut • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 25, 2026, 10:30 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

NCT06722417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icalcaprant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 25, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

NCT00707863
View directory record Official record
Conditions
Major Depression
Interventions
Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 25, 2026, 10:30 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 25, 2026, 10:30 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 10:30 PM EDT